Targets such as inhibitors of the MDMX-p53 response, histone deacetylase inhibitors, and spleen tyrosine kinase inhibitors have shown promise in the treatment of retinoblastoma, with minimal off-target effects in animal models or clinic trials [61, 62]. This evidence concerns the gene TP53 and retinoblastoma.